SG Americas Securities LLC Buys Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

SG Americas Securities LLC acquired a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 68,374 shares of the company's stock, valued at approximately $866,000. SG Americas Securities LLC owned 0.07% of Day One Biopharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in DAWN. Renaissance Technologies LLC purchased a new position in Day One Biopharmaceuticals in the second quarter valued at $994,000. Hsbc Holdings PLC acquired a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $163,000. Marshall Wace LLP increased its holdings in shares of Day One Biopharmaceuticals by 20.1% in the 2nd quarter. Marshall Wace LLP now owns 161,129 shares of the company's stock valued at $2,220,000 after acquiring an additional 26,958 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $2,570,000. Finally, AQR Capital Management LLC lifted its stake in Day One Biopharmaceuticals by 517.0% during the second quarter. AQR Capital Management LLC now owns 113,020 shares of the company's stock worth $1,557,000 after purchasing an additional 94,703 shares during the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 30,000 shares of the firm's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the completion of the transaction, the insider now owns 1,034,015 shares in the company, valued at $13,762,739.65. This trade represents a 2.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders sold 51,245 shares of company stock valued at $740,557. Corporate insiders own 8.40% of the company's stock.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock traded down $0.49 during midday trading on Friday, reaching $12.37. The company's stock had a trading volume of 849,469 shares, compared to its average volume of 1,044,328. The firm has a market capitalization of $1.25 billion, a PE ratio of -12.01 and a beta of -1.46. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $11.13 and a fifty-two week high of $18.07. The stock's 50 day simple moving average is $12.77 and its 200 day simple moving average is $13.76.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter last year, the business earned ($0.54) EPS. Equities analysts predict that Day One Biopharmaceuticals, Inc. will post -0.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on DAWN shares. Bank of America cut their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a report on Monday, November 4th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $35.86.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.